Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 14c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.69), $0.14 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Top Wealth Group expects net profit to double in fiscal 2026
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance